In 2020, the US Food and Drug Administration and the European Medicines Agency approved the use of bempedoic acid in adults with hypercholesterolemia. Bempedoic acid competitively inhibits ATP-citrate lyase in the pathway responsible for cholesterol synthesis. This results in decreased cholesterol synthesis by the liver, upregulation of LDL receptors, and subsequent clearance of circulating LDL. The CLEAR trials showed that bempedoic acid significantly lowered LDL in patients on high-intensity statins and in patients who were unable to tolerate statins owing to muscular side effects.
Preliminary data were promising for the use of lipoprotein lipase inhibitors for management of dyslipidemia, but evidence from clinical trials raised safety concerns.
Gene editing using CRISPR-CRISPR-associated protein 9 techniques have shown some evidence of efficacy in preclinical studies, but to date, no compounds are under investigation in humans.
Learn more about type 2 diabetes.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Anne L. Peters. Fast Five Quiz: Type 2 Diabetes and Dyslipidemia - Medscape - May 16, 2022.